NASDAQ:ASMB - Assembly Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.10 -0.12 (-0.79 %) (As of 05/21/2019 04:26 AM ET)Previous Close$15.22Today's Range$14.46 - $15.6552-Week Range$13.13 - $48.91Volume105,805 shsAverage Volume262,451 shsMarket Capitalization$385.81 millionP/E RatioN/ADividend YieldN/ABeta1.6 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in two Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in investigational new drug-enabling studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, and immuno-oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana. Receive ASMB News and Ratings via Email Sign-up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ASMB Previous Symbol CUSIP92282210 CIK1426800 Webwww.assemblybio.com Phone833-509-4583Debt Debt-to-Equity Ratio0.06 Current Ratio7.97 Quick Ratio12.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$14.80 million Price / Sales26.07 Cash FlowN/A Price / Cash FlowN/A Book Value$7.45 per share Price / Book2.03Profitability EPS (Most Recent Fiscal Year)($3.98) Net Income$-90,750,000.00 Net Margins-671.48% Return on Equity-56.45% Return on Assets-42.64%Miscellaneous Employees95 Outstanding Shares25,550,000Market Cap$385.81 million Next Earnings Date8/14/2019 (Estimated) OptionableOptionable Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions What is Assembly Biosciences' stock symbol? Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB." How were Assembly Biosciences' earnings last quarter? Assembly Biosciences Inc (NASDAQ:ASMB) issued its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.06) by $0.01. The biopharmaceutical company earned $3.89 million during the quarter, compared to analyst estimates of $3.81 million. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. View Assembly Biosciences' Earnings History. When is Assembly Biosciences' next earnings date? Assembly Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Assembly Biosciences. What price target have analysts set for ASMB? 5 brokerages have issued twelve-month price objectives for Assembly Biosciences' shares. Their forecasts range from $30.00 to $74.00. On average, they expect Assembly Biosciences' share price to reach $47.75 in the next twelve months. This suggests a possible upside of 216.2% from the stock's current price. View Analyst Price Targets for Assembly Biosciences. What is the consensus analysts' recommendation for Assembly Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Assembly Biosciences. Has Assembly Biosciences been receiving favorable news coverage? News coverage about ASMB stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Assembly Biosciences earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. Who are some of Assembly Biosciences' key competitors? Some companies that are related to Assembly Biosciences include Innoviva (INVA), Endo International (ENDP), Cambrex (CBM), Heron Therapeutics (HRTX), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Opko Health (OPK), Aimmune Therapeutics (AIMT), Corcept Therapeutics (CORT), Mallinckrodt (MNK), Phibro Animal Health (PAHC), Apellis Pharmaceuticals (APLS), Theravance Biopharma (TBPH), Epizyme (EPZM) and Inflarx (IFRX). What other stocks do shareholders of Assembly Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include AVEO Pharmaceuticals (AVEO), Exelixis (EXEL), FibroGen (FGEN), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), Amarin (AMRN), BioDelivery Sciences International (BDSI), Smart Global (SGH), Synergy Pharmaceuticals (SGYP) and Sorrento Therapeutics (SRNE). Who are Assembly Biosciences' key executives? Assembly Biosciences' management team includes the folowing people: Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 43)Dr. Uri A. Lopatin, Co-Founder, Chief Medical Officer and VP of R&D (Age 47)Dr. Richard J. Colonno, Exec. VP & Chief Scientific Officer of Virology Operations (Age 69)Mr. Thomas E. Rollins, Exec. Officer (Age 63)Mr. David J. Barrett CPA, Consultant (Age 43) Who are Assembly Biosciences' major shareholders? Assembly Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (9.68%), Wellington Management Group LLP (8.92%), BlackRock Inc. (6.81%), Janus Henderson Group PLC (3.73%), Victory Capital Management Inc. (2.20%) and Emerald Advisers LLC (1.83%). Company insiders that own Assembly Biosciences stock include Derek A Small, Uri A Lopatin and William R Ringo. View Institutional Ownership Trends for Assembly Biosciences. Which institutional investors are selling Assembly Biosciences stock? ASMB stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Marshall Wace LLP, Wellington Management Group LLP, Parametric Portfolio Associates LLC, Wells Fargo & Company MN, Renaissance Technologies LLC, Jennison Associates LLC and California State Teachers Retirement System. Company insiders that have sold Assembly Biosciences company stock in the last year include Uri A Lopatin and William R Ringo. View Insider Buying and Selling for Assembly Biosciences. Which institutional investors are buying Assembly Biosciences stock? ASMB stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, JPMorgan Chase & Co., Morgan Stanley, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Tibra Equities Europe Ltd, Prosight Management LP and Man Group plc. View Insider Buying and Selling for Assembly Biosciences. How do I buy shares of Assembly Biosciences? Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Assembly Biosciences' stock price today? One share of ASMB stock can currently be purchased for approximately $15.10. How big of a company is Assembly Biosciences? Assembly Biosciences has a market capitalization of $385.81 million and generates $14.80 million in revenue each year. The biopharmaceutical company earns $-90,750,000.00 in net income (profit) each year or ($3.98) on an earnings per share basis. Assembly Biosciences employs 95 workers across the globe. What is Assembly Biosciences' official website? The official website for Assembly Biosciences is http://www.assemblybio.com. How can I contact Assembly Biosciences? Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 833-509-4583 or via email at [email protected] MarketBeat Community Rating for Assembly Biosciences (NASDAQ ASMB)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 163 (Vote Outperform)Underperform Votes: 176 (Vote Underperform)Total Votes: 339MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Candlestick Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.